Enter multiple symbols separated by commas

Biotech and Pharmaceuticals Medicine


  • M Is For Boston Scientific And Pfizer Thursday, 14 May 2009 | 12:23 PM ET

    This takes the prize for the most dangerously optimistic acronym for a clinical trial. But MADIT (pronounced "made it") made it. Some folks with a lot of chutzpah at Guidant, now owned by Boston Scientific, apparently came up with the name for their big studies on implantable cardio defibrillators.

  • The Pfizer "Viagrat" Backstory Wednesday, 13 May 2009 | 1:23 PM ET

    Over the past few months I've blogged a couple of times about the public service announcement Pfizer produced in the UK to discourage guys from buying and taking counterfeit Viagra.

  • The Novartis Apprentice: You're Hired! Wednesday, 13 May 2009 | 11:16 AM ET
    Novartis Headquarters

    What does it say when a drugmaker hires a Goldman Sachs investment banker as its next Chief Financial Officer? That's the question I'm asking after Novartis announced that it's tapped a managing director of investment banking at Goldman Sachs, Jonathan Symonds, as its CFO apprentice.

  • Carl Icahn Takes On Biogen Idec ... Again Tuesday, 12 May 2009 | 10:23 AM ET
    Carl Icahn

    Billionaire activist investor (It seems it's become almost de rigueur to put those three words before his name) Carl Icahn is apparently so busy waging a proxy fight against biotechs Amylin Pharmaceuticals and Biogen Idec that he hasn't posted a new blog entry in nearly a month.

  • Hospitals Begin to Move Into Supermarkets Tuesday, 12 May 2009 | 10:14 AM ET

    As walk-in clinics at stores like CVS and Wal-Mart offer convenient alternatives to doctors’ offices and hospital emergency rooms, some hospitals are fighting back - with walk-in clinics at some of those same retailers.

  • There's No ME in aMYlin Monday, 11 May 2009 | 10:19 AM ET

    Imagine my surprise when I got an email over the weekend from "Diabetic Investor" newsletter editor David Kliff informing me that Amylin Pharmaceuticals is quoting me in a letter to shareholders.

  • Taking A Shot At GlaxoSmithKline Friday, 8 May 2009 | 12:18 PM ET

    The Glaxo announcement contained the results of the first head-to-head study of GSK’s Cervarix versus Merck’s Gardasil. They’re the shots for the sexually transmitted virus that can cause genital warts and cervical cancer. MRK’s is already on the market. GSK’s has been delayed in getting there.

  • Merck Cancer Shot Offers Longer Protection: Study Friday, 8 May 2009 | 6:35 AM ET

    A new study shows that Merck's Gardasil vaccine protects some young women from a strain of a sexually transmitted disease that can lead to cervical cancer for nearly a decade.

  • Vanda Snaps Victory From The Jaws Of Defeat Thursday, 7 May 2009 | 3:50 PM ET

    Out of nowhere late yesterday the FDA approved VNDA's schizophrenia drug with the funky name Fanapt.

  • New Effort Reopens a Medical Minefield Thursday, 7 May 2009 | 10:52 AM ET

    The Obama administration plans to spend $1.1 billion over the next few years on comparative studies to determine the effectiveness of competing treatments for common conditions like back pain, heart disease and prostate cancer.

  • Cheaper Generic Pills Saved US $734 Billion: Lobbyists Thursday, 7 May 2009 | 5:37 AM ET

    Against the backdrop of President Obama's healthcare reform effort, the main lobbying group for the generic drug industry says the U.S. healthcare system saved nearly three-quarters of a trillion dollars over the past ten years on generic drugs.

  • Roche & Genentech: Get It Together Wednesday, 6 May 2009 | 12:32 PM ET

    It's a new world. Before Roche bought Genentech, stock-moving drug development milestones for DNA were closely followed by the news media, analysts and investors. But because the Swiss drugmaker Roche only trades over-the-counter in the U.S., the information isn't as "actionable" as it used to be when DNA was around.

  • Battlin' Over Amylin Wednesday, 6 May 2009 | 11:07 AM ET

    You gotta love a good proxy fight, especially when you have one of the kings of shareholder activism, Carl Icahn, in the ring. And lately, I've been getting bombarded by emails from representatives of all corners.

  • Cinco de Mayo Para Byetta Tuesday, 5 May 2009 | 12:22 PM ET

    Fiesta time started a little earlier than expected for investors in Eli Lilly, Amylin Pharmaceuticals and Alkermes. The companies had said they would file for Food and Drug Administration approval of the once-a-week version of the diabetes drug Byetta in the second quarter, but most analysts thought that meant June.

  • May Day For Dendreon? Monday, 4 May 2009 | 11:05 AM ET

    Whenever a politician, government agency or company puts out news late on a Friday chances are it probably isn't good or it's stuff they'd like to just slip under the door.

  • Genentech's Desmond-Hellmann May Take Helm At UCSF Friday, 1 May 2009 | 3:37 PM ET
    Dr. Susan Desmond-Hellmann

    Well, it didn't take long. A little more than a month after Roche swallowed Genentech, Dr. Susan Desmond-Hellmann may be headed out the door sooner than anyone thought.

  • After Dendreon Week, Time For Lilly's LeWeekend Friday, 1 May 2009 | 10:05 AM ET

    have two reasons to exhale on this TGIF. My month-long stint on the graveyard shift anchoring "Worldwide Exchange" is over and Dendreon is done...for now. After all, Dendreon and its prostate cancer treatment Provenge is the story that just keeps on giving.

  • The Sequenom Syndrome Thursday, 30 Apr 2009 | 12:01 PM ET

    Shares of San Diego-based Sequenom are sinking on huge trading volume. The company shocked investors after the closing bell yesterday when it issued this press release announcing that its data couldn't be trusted.

  • The Morning After For Dendreon Wednesday, 29 Apr 2009 | 2:02 PM ET

    The herky-jerky, stop-and-go cab ride I'm taking right now to O'Hare ain't nuthin' compared to yesterday's roller coaster ride at Chicago's McCormick Place. And can I just say? Is Dendreon  a giant magnet for high drama and intrigue or what?

  • Feeding At The Swine Flu Trough Tuesday, 28 Apr 2009 | 9:31 AM ET

    Here we go again. When I was relatively new on this beat I was thrown into covering the bird flu scare. At the time, many experts said it wasn't a question of if, but when it would come to the U.S. I'm still waiting. And I hope we're all waiting forever.